Leveraging global relationships in response to comparator drug discontinuation delivers study success

While globalisation and the rapid development of innovative new drugs are contributing to improved human health, it is also introducing additional challenges for sponsors to overcome.

Comparator sourcing is no exception. Take for example the field of oncology, which already makes up 25 per cent of the global late stage pipeline and where innovation in cancer drug development is predicted to continue to surge over the next five yearsi. With most investigational products studied against the existing standard of care, the demand for comparator products in this therapeutic area – as well as others - is forecast to rise dramaticallyii . Indeed, patterns are already beginning to emerge that indicate that timely availability of comparator products (or a lack there of) are posing a significant threat to clinical trials.

Download this case study to find out more.

i A. M. Huss Analyzing Trends in Global Comparator Sourcing and Distribution in 2015 – A Preview-Journal of Clinical Research. April 2015
ii http://www.quintiles.com/~/media/library/white%20papers/expected-growth-of-industry-sponsored-clinic